Restless Genital Syndrome Induced by Milnacipran

Keita Miyake, Manabu Takaki, Shinji Sakamoto, Kiyohiro Kawada, Shinichiro Inoue, Norihito Yamada

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)


Objectives Restless genital syndrome (RGS) includes discomfort, pain, numbness, vibration, restlessness, or a burning sensation involving the vagina, perineum, pelvis, penis, and proximal portion of the lower limbs in patients. The RGS has been sometimes reported in Parkinson disease. In patients without Parkinson disease, RGS is also known as persistent genital arousal disorder (PSAS), which includes uncontrollable genital arousal, with or without orgasm or genital engorgement, unrelated to sexual desire. Although withdrawal from selective serotonin reuptake inhibitors antidepressants is reported to induce PSAS, there is no report of RGS or PSAS induced by antidepressants. Methods We obtained the consent for the presentation and have not identified individuals for ethical reasons. Results We first report a woman patient with depression induced RGS by milnacipran (MLN). Conclusions We discuss the relationship with restless legs syndrome and the difference from akathisia. It is highly possible MLN affected her RGS because she experienced RGS for the first time after the dose of MLN was increased. A limitation of this report is that we stopped MLN and administered gabapentin enacarbil immediately. We should join MLN to the list of compounds suspected of inducing RGS.

Original languageEnglish
Pages (from-to)109-110
Number of pages2
JournalClinical Neuropharmacology
Issue number3
Publication statusPublished - May 1 2018


  • depression
  • gabapentin enacarbil
  • milnacipran
  • restless genital syndrome
  • restless legs syndrome

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'Restless Genital Syndrome Induced by Milnacipran'. Together they form a unique fingerprint.

Cite this